Relmada Therapeutics Inc

NASDAQ:RLMD  
25.84
-0.44 (-1.67%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Relmada Therapeutics Inc Stock, NASDAQ:RLMD

880 3rd Avenue, 12th floor, New York, New York 10022
United States of America
Phone: +1.646.876.3459
Number of Employees: 14

Description

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It focuses on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist, which is a New Chemical Entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.